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Background/aim: Phyllodes tumors (PTs) of the breast are rare, and their diagnosis and treatment remain controversial. This
retrospective study aims to examine the clinical outcome of benign and borderline PTs, according to the surgical margins.
Materials and methods: We examined the medical records of 122 patients in our clinic, who had histologically confirmed benign and
borderline PTs between 1994 and 2017.
Results: The mean age of the patients was 40.6 years (range 18.0–81.0, ±12.1 standard deviation [SD]) and the mean tumor size was 25.8
mm (range 9–65, ±10.3 SD). All patients underwent a breast-conserving procedure and the median follow-up was 51 months. Tumor
margins were positive (tumor touching the ink) in 43 patients (35%). Only 16 patients (13%) had margins ≥10 mm. The margins were
between 2 and 10 mm in most patients (40%) and ≤1 mm in 12% of the patients.
Conclusion: Although no re-excision was performed to obtain grossly clear margins, local recurrence was not observed in any patients.
Therefore, revision surgery for close or positive surgical margins for benign and borderline PTs should not be performed as a rule. As
most tumors recur within 2 years of diagnosis, we propose a close clinical and imaging follow-up during this period.
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1. Introduction
Phyllodes tumors (PTs) are rare fibroepithelial tumors
of the breast that account for less than 1% of all primary
breast tumors (1,2). They were first described by Johannes
Muller in 1838 as “cystosarcoma phyllodes” (3). However,
in 1982, the World Health Organization (WHO) declared
a more suitable term of “phyllodes tumor”, which has been
widely accepted (4).
Benign PTs are more frequent, with an incidence of
35%–85%. Borderline PTs, on the other hand, account for
7%–40% of cases (5). Local recurrence rates vary in the
literature, and are reported to be approximately 8% for
benign PTs and 21% for borderline cases (6).
The macroscopic appearance of most PTs is that of a
circumscribed, round to oval multinodular mass that lacks
a true histologic capsule. Most PTs are indistinguishable
from fibroadenomas (FAs) on gross examination.
Histologically, PTs of the breast show the characteristic
appearance of leaf-like architecture, increased stromal
overgrowth, cellularity, atypia, and mitosis (7). According
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to the WHO, three histologic types are identified based
on histopathological features: benign, borderline, and
malignant (4).
Diagnosis of PTs with imaging methods is generally
difficult and they are often confused with FAs. On
mammography (MG), PTs have smooth, round-to-oval
margins with lobulation. On ultrasonography (US), PTs
are generally heterogeneous, well-defined, hypoechoic
oval lesions surrounded by a capsule or pseudocapsule,
and show lobulation. However, internal echoes and
calcifications are absent (8).
Surgery is the main treatment for PTs of the breast.
Nevertheless, the extent of initial resection and the
necessity for re-excision to have adequate margins
remain controversial. Both PTs and FAs are on the same
morphological spectrum; hence, it can be very difficult
to differentiate these entities clinically, radiologically,
and in terms of tissue sampling. Patients usually undergo
enucleation of this innocuous breast lump, the diagnosis
of which results from PTs. The question regarding these
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patients is whether or not to obtain wide excision margins
to achieve local disease control and spare them the
potential cosmetic and psychological problems that may
arise with resurgery.
In this retrospective study, we aimed to investigate
clinical outcomes of 122 benign and borderline PTs of the
breast, treated and followed-up in a single institution, to
better characterize both surgical management patterns
and clinical behavior of these rare tumors, according to
surgical margins at first resection.
2. Materials and methods
The medical records of 122 patients with histologically
confirmed benign and borderline PTs operated on at
our clinic between 1994 and 2017 were retrospectively
reviewed. Informed consent was obtained from all patients
during hospitalization.
The clinical data analyzed included patient
demographics, radiologic methods used for diagnosis,
tumor size, localization, and type of surgery.
Histopathologic features of the tumor, as well as patient
follow-up data and outcomes, were evaluated.
Preoperative MG and US were evaluated by our breast
radiologist in the Department of Radiology, Dokuz Eylül
University. All patients were evaluated according to the
American College of Radiology (ACR) Breast Imaging
Reporting and Data System (BI-RADS). Atlas (5th edition)
was used in all imaging methods.
As PTs may be difficult to distinguish preoperatively
from cellular FAs due to their heterogeneous nature,
neither fine needle aspiration cytology (FNAC) nor core
needle biopsy was performed as the initial management.
Operative treatment was defined as wide local excision
(WLE), enucleation, or wire-guided surgery (WGS).
Patients with palpable mass underwent WLE. WGS,
which has abnormal radiologic findings without palpable
mass, was used in patients. Enucleation of the tumor was
performed in patients that had been diagnosed with FAs
peroperatively.
All the histologic slides were examined by our breast
pathologist in the Department of Pathology, Dokuz Eylül
University. The tumors were classified according to the
WHO classification of breast tumors. Data on tumor size
and margins (negative or positive, and minimum tumorfree margin) were obtained.
We subdivided the tumors into 4 groups based on the
nearest resection margins: (1) positive resection margin,
(2) resection margin ≤ 1 mm, (3) resection margin between
2 mm and <10 mm, and (4) resection margin ≥ 10 mm.
Regular clinical and imaging follow-up of all the
patients were similar during the first 2 years after surgery.
Statistical Package for the Social Sciences (SPSS Inc.,
Chicago, IL, USA) 20.0 was used for statistical analyses.

Categorical variables were expressed as percentages and
continuous variables as means, median, standard deviation
(SD), and range.
3. Results
3.1. Clinical characteristics
From 1994 to 2017, a total of 122 female patients with a
mean age of 40.6 years (range 18.0–81.0, ±12.1 SD) were
included in the study. The mean ages for benign and
borderline PTs were 39.3 and 50.5 years, respectively. The
characteristics of the patients are summarized in Table 1.
Most patients (90%) presented with palpable, mobile,
and painless masses in their breasts. In 12 (10%) patients,
the diagnosis was based on abnormal radiologic findings.
In 58 (47.5%) patients, the tumor was located in the
right breast, and in 64 (52.5%), it was located in the left
breast. All patients presented with a unilateral breast lump
at diagnosis.
3.2. Imaging findings
MG was performed in 46 (37.7%) patients, of whom 33
(71.7%) were classified as suspicious (BI-RADS ≥ 4). In US
imaging, this was performed in all patients, 105 (86.0%)
of which were classified as suspicious (Table 1). PTs were
suspected in 63 (51.6%) patients during imaging analyses.
3.3. Primary treatment
All patients underwent surgery. A total of 67 (55.0%)
patients were treated with WLE, 43 (35.0%) with
enucleation, and 12 (10.0%) with WGS (Table 2).
No patients underwent axillary lymph node dissection.
Adjuvant therapy was not given.
3.4. Histopathologic features
The histopathologic characteristics of the cases are
summarized in Table 2. One hundred and eight (88.5%)
tumors were benign PTs and 14 (11.5%) were borderline
on histopathological analyses. The mean tumor size was
25.8 mm (range 9–65, ±10.3 SD). Surgical margin data
were available for all patients.
(1) 35% (n = 43) of patients had positive surgical
margins after surgery (tumor touching the ink). All
patients with positive margins had benign PTs.
(2) 12% (n = 14) of patients had margins ≤ 1 mm (close
margins, but no tumor on ink).
(3) 40% (n = 49) of patients had margins between 2
and <10 mm.
(4) 13% (n = 16) of patients had margins ≥ 10 mm.
3.5. Follow-up
The median follow-up was 46 ± 57.6 months (range 0–277)
in benign PTs and 133 ± 67.2 months (range 36–240) in
borderline PTs (Table 2).
All 43 patients with positive margins had benign
histology. Re-excision was not performed in these patients,
who were closely followed-up by physical examination

29

SEVİNÇ et al. / Turk J Med Sci
Table 1. Patient and lesion characteristics (n = 122).
Mean ± SD (range)
Age mean (years)

n (%)

40.6 ± 12.1 (18–81)

Preoperative diagnostic modalities

Mammographic impression (n = 46)

Echographic impression (n = 122)

Tumor laterality

By palpation

110 (90)

By radiologic findings

12 (10)

BI-RADS 3

13 (28.4)

BI-RADS 4a

27 (58.6)

BI-RADS 4b

4 (8.7)

BI-RADS 4c

2 (4.3)

BI-RADS 3

17 (13.9)

BI-RADS 4a

99 (81.1)

BI-RADS 4b

4 (3.3)

BI-RADS 4c

2 (1.6)

Left

64 (52.5)

Right

58 (47.5)

Table 2. Histopathological characteristics (n = 122).
Benign
(n = 108)

Borderline
(n = 14)

Total
(n = 122)

Size

26.1 ± 10.6

23 ± 7.5

25.8 ± 10.3

Mean ± SD (range)

(9–65)

(11–35)

(6–5)

108 (89)

4 (3)

112 (92)

0–4
Mitosis, n (%)

Surgical margins, n (%)

Type of surgery, n (%)

Follow-up (months)

5–10

-

9 (7)

9 (7)

>10

-

1 (1)

1 (1)

Positive

43 (35)

-

43 (35)

≤1 mm

13 (11)

1 (1)

14 (12)

2–<10 mm

40 (33)

9 (7)

49 (40)

≥10 mm

12 (10)

4 (3)

16 (13)

Enucleation

43 (35)

-

43 (35)

Wide local excision

55 (45)

12 (10)

67 (55)

Wire guided

10 (8)

2 (2)

12 (10)

Median

46 ± 57.6

133 ± 67.2

51 ± 63.1

Range

(0–277)

(36–240)

(0–277)

and imaging methods. The median follow-up within this
group of patients was 39 months (range 1–277). There was
no local recurrence during the follow-up period.
4. Discussion
PTs of the breast are rare, representing <1% of all
breast neoplasms (1,2). The WHO categorizes these
tumors as benign, borderline, and malignant, based
on histopathologic characteristics (4). Their prognosis
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and clinical outcome are still associated with much
uncertainty and variability. In addition, malignant PTs
commonly show more aggressive behavior, both locally
and systemically, compared to their benign and borderline
counterparts (9). In this study, we investigated benign
and borderline PTs of the breast treated, diagnosed, and
followed-up at our institution, to better characterize both
surgical management patterns and the clinical behavior of
these tumors.
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PTs may occur at any age, with a mean age ranging
between 30 and 52 years (10). In our study, all patients
were female with a mean age of 40.6 years at diagnosis,
which is similar to other series.
Painless palpable mobile mass in the breast was the
most common presenting symptom in our series (90.0%).
Tumor size ranged from 9 to 65 mm, with a mean size of
25.8 mm. In several studies in the literature, the size of PTs
of the breast varies between 0.5 and 27 cm, with a mean
between 5 and 7.2 cm (11). In contrast, the mean tumor
size in our series seems to be considerably smaller.
PTs were localized in either breast in almost equal
proportion (47.5% vs. 52.5%) in our study, similar to
several other series (12).
The role of imaging is uncertain in diagnosis due to
lack of specific characteristics. PTs and FAs have similar
MG and US features (8). We performed US as the firststep imaging method in all patients in our study. MG
was performed only in patients aged more than 40 years.
Diagnosis of PTs was suspected in 63 (51.6%) patients
during imaging analyses in our series, a ratio that was
higher than that in the literature (13). WGS was performed
on 12 (10%) patients who presented with abnormalities
detected during imaging analyses without a palpable mass.
FNAC of the breast has low sensitivity (72.0%) to
differentiate the type of histology (14,15). Moreover,
false-negative results can be obtained when sampling
is performed in an area of hypocellular stroma (11).
Core needle biopsy is more acceptable than FNAC for
obtaining a correct diagnosis, as it can provide specific
histopathologic findings. However, its false negative rates
are reported as high as 30.0% in the literature (16).
As PTs may be difficult to diagnose with cytologic
and histologic methods preoperatively due to their
heterogeneous nature, none was the preferred choice
of first-line management in our institution. Instead,
excisional biopsy was performed to achieve an accurate
diagnosis with examination of the entire mass. This
approach increased cost-effectiveness.
Surgery remains the cornerstone of treatment for
PTs of the breast. However, due to their unpredictable
clinical presentation, uncertain pathological behavior,
and inaccurate preoperative diagnosis, there still seem to
be dilemmas in their treatment plans (11). Enucleation
of the tumor is frequently preferred, since the majority
of these lesions are diagnosed as FAs preoperatively (15).
The question in PT cases, however, is whether or not all
these patients should undergo a second operation to
provide adequate clear margins. In the literature, there is
no consensus about the necessity of a surgical revision of
margins in such cases.
Numerous clinical studies recommend wide excision
of the tumor with a 10-mm clear margin (12,17–21),
which causes major difficulties in achieving good cosmetic

results. However, recent data show that there is no direct
relationship between the margin status or width of
negative margins and recurrence (22,23). Kim et al. have
suggested that recurrence rates are very low for benign
PTs, regardless of margin status, even for patients treated
with local excision (24). In addition, Yom et al. have
reported that margin status is not associated with risk of
local recurrence (15). In their series of 164 PT cases, Jang
et al. found that a 10-mm negative margin thickness did
not confer any local control advantage over a narrower
negative margin (22). Onkendi et al. have shown that
the extent of surgical resection did not affect disease-free
survival in patients with borderline and malignant PTs
(23). In addition, there are certain series in the literature
that report recurrence in PT cases with negative margins at
initial surgery (12,17). In their largest series, Zurrida et al.
advocated a wait-and-see policy for patients with benign
and low-grade tumors and positive surgical margins,
due to lower recurrence rates (25,26). In our series, we
performed complete surgical resection with safe margins
in clinically and radiologically suspected benign PTs or
tumors of undetermined clinical significance.
In our study, 35% of patients had positive surgical
margins and 12% had close margins of less than 1 mm.
This might be explained by the fact that the majority of
benign tumors were diagnosed peroperatively as FAs, and
enucleation of the tumors were, therefore, performed.
None of the patients underwent reoperation to increase
the margin. In agreement with this, Tan et al. suggest a
conservative approach to benign PTs that have initially
been enucleated without margins, and excision with
negative margins should be achieved for recurrent and
malignant PTs (14). This is supported by the MD Anderson
Cancer Center clinical practice algorithm for PTs, which
recommends that if initial excision has a negative margin
in benign PTs, further surgery is not required (15). Despite
positive and very close margins (47.0%) in our study, we
have no local recurrence, whereas local recurrence rates in
other series vary from 8.0% to 13.0% (6,12,19,21). This may
be explained by the fact that these studies do not separate
benign or borderline PTs from high-grade malignant PTs
in evaluation (12,22,27).
Several factors have been found to be related to local
recurrence. Tumor size and mitotic activity were found to
be independently associated with local recurrence, whereas
margin status and surgical procedure were not. The risk
of local recurrence is higher in larger tumors and tumors
with >10 mitosis per 10 high power fields. In our series,
mean tumor size was 25.8 mm and 121 (99.0%) patients
had <10 mitosis per 10 high power fields. In agreement
with our results, several authors have proposed that reexcision should be performed in tumors with high mitotic
activity (15,20,21). Moreover, local recurrence of benign
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and borderline tumors can be well managed by further
surgery (either breast-conserving surgery or mastectomy).
PTs show unpredictable behavior of histotypes.
Metastases are more common in malignant PTs. In a
similar manner, we have no metastases in our series
(17,21,22). Nevertheless, several authors have described
local recurrence and even distant metastases of benign and
borderline tumors (18,19,21,22).
In this study, the median follow-up was 46 months
in benign and 133 months in borderline PTs. The mean
duration of time-to-recurrence varies in the literature,
but most tumors recur within 2 years from diagnosis
(20,21,25–27). Therefore, it seems that most recurrences
can be detected during this time frame with appropriate
follow-up.
Our findings suggest that patients with benign and
borderline PTs have a less aggressive disease course and

low risk of local recurrence, irrespective of margin status.
Reoperation with wider resection in healthy tissue is not
justified in selected patients. There is no evidence-based
recommendation for delineating an optimal length of
follow-up or follow-up intervals. Nevertheless, beginning
with clinical and radiological reviews at 6 months and
continuing for the first 2 years after surgery, followup of yearly evaluation may be an appropriate practice
suggestion.
Our study may lead to new perspectives in the surgical
management of patients with benign or borderline PTs
of the breast, enable patients feel good about their breast
cosmesis, and prevent tumor recurrence efficiently.
However, our data have limited capacity for making
firm assumptions, as this is a retrospective study. The
results of prospective trials and similar studies are
warranted to support our results.
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